MIRACLE Part A Enrollment Complete: Operational Signal, Zero Efficacy Data, Q1 2027 Is Everything

Moleculin Completes Part A Enrollment for MIRACLE Trial in R/R AML

Moleculin Biotech, Inc. has announced the completion of enrollment for Part A of its pivotal Phase 2/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML). A total of 89 subjects have been enrolled, with one additional subject in screening, keeping the program on track for a comprehensive data readout in the first quarter of 2027. The rapid enrollment highlights the significant unmet need in R/R AML and strong investigator engagement. The expanded Part A dataset is expected to provide important insights into AnnAraC's potential efficacy across various first-line AML treatment approaches, including intensive 7+3 chemotherapy and venetoclax-based regimens.

• The MIRACLE trial's Part A is designed as a randomized, double-blind study comparing two different doses of Annamycin plus cytarabine against a control arm of cytarabine plus placebo, with all outcomes measured after a single cycle of therapy. The full Part A population is anticipated to have an approximate 50/50 split between "fit" and "unfit" subjects, offering valuable insights into Annamycin's potential across diverse R/R AML patient groups, a notable shift from the initial 70/30 split.
• Annamycin continues to demonstrate an absence of cardiotoxicity in the blinded data from the MIRACLE trial, a key differentiating factor from conventional anthracyclines. This favorable safety profile, combined with its design to avoid multidrug resistance mechanisms, positions Annamycin to address critical unmet needs in R/R AML, particularly in challenging patient environments where cardiotoxicity can be a limiting factor.
• The completion of Part A enrollment represents a significant operational milestone for Moleculin, underscoring the company's strong execution capabilities in a global, randomized AML trial. The upcoming comprehensive data readout in Q1 2027 is expected to be substantially more detailed than previous interim analyses, which will be crucial for supporting the selection of an optimal Annamycin dose for advancement into Part B of the MIRACLE study and potentially defining the program's future.

The Urgent Need for New Therapies in Relapsed/Refractory AML

Relapsed/refractory (R/R) AML remains one of oncology's most pressing therapeutic challenges, with outcomes remaining poor across most molecular subgroups despite recent advances in targeted therapy. Several high-risk populations have emerged as focal points for clinical development, driven by distinct resistance mechanisms and a lack of durable treatment options.

• KMT2A-rearranged and NPM1-mutated AML: Menin inhibitors (revumenib, ziftomenib, bleximenib, enzomenib, BMF-219) have demonstrated composite complete remission rates of 20–35% and overall response rates of 45–65% in heavily pretreated R/R disease. However, outcomes after menin inhibitor failure remain poor, with a median overall survival of 4.4 months from the start of next therapy. Acquired mutations in the menin gene have been identified in 39% of post-revumenib relapses, and FLT3-ITD, WT1, and MEN1 mutations are associated with resistance, underscoring the need for strategies to overcome or prevent resistance in this population.

• TP53-mutated AML: TP53 mutations represent one of the worst prognostic factors in AML, with affected patients facing a relapse-free survival of just five-to-six months compared to TP53 wild-type patients. This population remains refractory to conventional cytotoxic chemotherapies, targeted therapies, and allogeneic stem cell transplantation. Although hypomethylating agent/venetoclax-based regimens yield improved initial responses, remissions are generally short-lived and overall survival remains poor. Emerging approaches — including p53 reactivators, MDM2/X regulators, apoptotic activators targeting BIRC5/survivin, cell-cycle modulators, and immune- and metabolic-based therapies — show preclinical promise but lack definitive clinical efficacy to date.

• Venetoclax- and FLT3-inhibitor-refractory AML: RAS pathway activation — via selection for RAS mutant clones, non-mutational upregulation of RAS transcriptional programs, and a shift to RAS-associated monocytic AML differentiation — has been identified as a central resistance mechanism to venetoclax and FLT3 inhibitor (gilteritinib) combination therapy. In the R/R setting following menin inhibitor failure, no FLT3-mutant patients responded to gilteritinib (0/6 gilteritinib-naïve), highlighting the depth of the unmet need in this subgroup.

• Monocytic (FAB M4/M5) AML: Monocytic leukemia exhibits intrinsic and extrinsic resistance to both venetoclax and MDM2 inhibitors, driven by a CEBPB/IL-1β/TNF-α feedback loop that suppresses caspase activation, upregulates MCL1 and BCL2A1, and extrinsically protects blasts via aberrant monocyte-derived inflammatory cytokines. This subtype remains inadequately addressed by current standard-of-care regimens, with combination strategies targeting the IL-1/TNF-α pathway under active investigation.

• MRD-positive patients in remission: MRD positivity during and after treatment is associated with higher relapse rates and worse overall survival, yet MRD testing approaches remain non-standardized, limiting consistent prognostication and clinical intervention. Development of highly sensitive molecular MRD detection methods — particularly for NPM1-mutated and KMT2A-rearranged subgroups in the context of novel therapies — is identified as a key priority to guide treatment decisions and reduce relapse risk.

Unpacking the MIRACLE Trial Design for Relapsed/Refractory AML

Two trials in the relapsed/refractory AML setting provide detailed study design and endpoint data.

The quizartinib phase 2 study (NCT02984995) was a multicenter, single-arm, two-stage study enrolling Japanese patients with FLT3-ITD positive relapsed/refractory AML. The gemtuzumab ozogamicin (GO) phase IV study (NCT03727750) enrolled patients aged ≥ 18 years with relapsed/refractory CD33-positive AML receiving the fractionated GO dosing regimen.

Annamycin's Advance: A New Hope for R/R AML

The completion of enrollment for Part A of the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) marks a significant milestone in a therapeutic area desperately in need of innovation. For patients battling R/R AML, the prognosis remains grim, with limited effective options, especially after the failure of venetoclax-based therapies, which have become a cornerstone of treatment but are frequently met with resistance and subsequent relapse. The rapid pace of enrollment in the MIRACLE trial itself speaks volumes, reflecting the urgent clinical demand for novel agents and strong investigator belief in Annamycin's potential.

Annamycin, a novel anthracycline, is being evaluated in combination with cytarabine (AnnAraC). This approach aims to leverage a distinct mechanism of action that could circumvent resistance pathways commonly encountered with conventional chemotherapies or BCL-2 inhibitors. The hope is that AnnAraC can offer a more effective and potentially better-tolerated option than existing intensive regimens, which are often associated with severe myelosuppression and infectious complications.

However, the path forward is not without its challenges. The R/R AML population is notoriously difficult to treat, characterized by high rates of relapse and resistance, even to advanced therapies. Any new regimen must demonstrate not only significant response rates but also durable efficacy in the face of complex disease biology. Furthermore, the inherent toxicities of intensive chemotherapy, including profound cytopenias and increased risk of infection, remain a critical consideration for patient safety and tolerability. The diverse genetic landscape of AML, with mutations like KIT, TP53, and NPM1 influencing disease progression and treatment response, also means that a successful therapy must exhibit broad activity across these varied subgroups. The upcoming data readout in early 2027 will be pivotal, offering crucial insights into AnnAraC's efficacy and safety profile, and determining its potential to truly reshape the treatment paradigm for this high-risk patient population.